Rectal Cancer Patients Clinical Trial
— MA_LARSWEXOfficial title:
Validation of the Morocan Arabic Version of the Low Anterior Resection Syndrome (LARS) Score for Measuring Bowel Dysfunction and Wexner Score of Incontinence After Sphincter-preserving Surgery Among Rectal Cancer Patients
Verified date | February 2020 |
Source | Moroccan Society of Surgery |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Observational |
In the past decade, colorectal cancer management improved considerably with total mesorectal
excision as well as the multidisciplinary management relying on neoadjuvant
radiochemotherapy. This forward leap is currently responsible for an increase in the
survivorship of colorectal cancer patients to more than 50% at 5 years. Additively the
surgical approach is now more inclined towards sphincter preserving procedures, which allows
the conservation of body image but can have negative bowel function repercussions consisting
of urgency and incontinence ; all these terms encompassed in the low anterior resection
syndrome.
In the light of these findings many studies developed assessment tools in order to
objectively measure this functional alteration among which are the low anterior resection
syndrome questionnaire (LARS) and the WEXNER score. These tools designed to assess bowel
function after sphincter-preserving surgery are now translated and validated into various
languages and used in different countries.
The LARS score relies on the frequency of the symptoms and allows the categorization of
patients into 3 groups: no LARS (0-20 points), minor LARS (21-29 points), and major LARS
(30-42 points). It assesses the frequency of emptying, incontinence ( liquid, gas ), and
other symptoms such as urgency and incomplete voiding. On the other hand, the WEXNER score
relies on the examination of the frequency of three types of fecal incontinence (solid,
liquid, and gas) and their consequences (pad wearing and lifestyle alteration) with frequency
options ranging from never (score 0) through to always (meaning at least once per day; score
4). The score ranges from 0 (perfect continence) to 20 (complete incontinence).
The aim of our study is to adapt and validate the LARS and WEXNER score to the moroccan
arabic dialect.
Status | Completed |
Enrollment | 143 |
Est. completion date | October 31, 2019 |
Est. primary completion date | October 31, 2019 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility |
Inclusion Criteria: - Patients aged older than 18 years. - Neoplasm of the rectum. - Rectal cancer patients undergoing curative sphincter-preserving surgery with (partial or total) mesorectal excision. - Surgery performed between January 2012 to March 2019, with reversal of the defunctioning stoma before March 2019; - Bowel continuity restoration for at least 6 months. - Consent to participate in the study. Exclusion Criteria: - Palliative surgery. - The presence of a definitive iliac or perineal stoma. - Diseases of bowel dysfunction (Crohn's disease) - Cognitive and/or language issues. |
Country | Name | City | State |
---|---|---|---|
Morocco | National Institut of Oncology, Surgical oncology department | Rabat | Please Enter The State Or Province |
Morocco | Private surgical oncology center | Salé |
Lead Sponsor | Collaborator |
---|---|
Moroccan Society of Surgery | Institut National d'Oncologie Sidi Mohammed Ben Abdellah |
Morocco,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Validation of the moroccan arabic version of the LARS score | Validation of the Moroccan arabic Low anterior resection syndrome (LARS) score ; 0 to 20 (no LARS), 21 to 29 (minor LARS ) and 30 to 42 (Major LARS ) | 6 months after surgery | |
Primary | Validation of the moroccan arabic version of the Wexner score | validation of the Moroccan arabic Wexner score; 0 perfect score and 20 complete incontinence | 6 months after surgery |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT03569488 -
Validation of the French Version of the Low Anterior Resection Syndrome (LARS) Among Rectal Cancer Patients
|
||
Withdrawn |
NCT01426074 -
DCE-MRI PET Bevacizumab Study in Rectal Cancer
|
Phase 2 |